CD47 and cancer: First, an SIPRα variant (SαV) which showed superior affinity to CD47 was engineered on the surface of cancer cells.[85] And then, three kind of vesicles are fused, including SIPRα variant‐cancer cell nanovesicles (SαV‐C‐NVs), M1 TAM nanovesicles (M1‐NVs), and platelet nanovesicles (P‐NVs).